Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

More on GLP-1 and incretin signalling

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026